5 results match your criteria: "Maanshan Municipal Hospital Group[Affiliation]"
MAGE3 and Survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer.
Oncol Lett
June 2018
Maanshan Center for Clinical Laboratory, Maanshan, Anhui 243000, P.R. China.
Dendritic cell (DC) immunotherapy is an optimal cancer treatment, resulting in its emergence as a therapeutic choice; however, there are limited studies investigating dual antigen-pulsed DC immunotherapy in non-small cell lung cancer (NSCLC). In order to determine the effect of a recombinant melanoma-associated antigen (rMAGE-3) and recombinant Survivin (rSurvivin) peptide-pulsed DC immunotherapy in patients with NSCLC, the present clinical study was performed. DC immunotherapy was generated from the monocytes of patients with NSCLC and primed with rMAGE-3 and rSurvivin peptides.
View Article and Find Full Text PDFAccuracy of microRNAs for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.
Clin Res Hepatol Gastroenterol
September 2016
Maanshan Center for Clinical Laboratory, Maanshan Municipal Hospital Group, 45, Hubei Road, Maanshan 243000, China.
Due to the high morbidity, mortality and late detection of hepatocellular carcinoma (HCC), it becomes a major public health challenge. MicroRNAs (miRNAs) have been reported to be aberrantly expressed in patients with HCC and thus may serve as potential diagnostic biomarkers. The aim of this study was to systematically assess the diagnostic accuracy of miRNAs as biomarkers for diagnosing HCC through a meta-analysis.
View Article and Find Full Text PDFPemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer.
Int J Clin Exp Pathol
October 2016
Maanshan Center for Clinical Laboratory, Maanshan Municipal Hospital Group Maanshan, Anhui, China.
Lung cancer is the leading cause of cancer-related mortality. This study was undertaken to investigate the efficacy and safety of adding regulatory T cell inhibitor cyclophosphamide to pemetrexed therapy for the second-line treatment of NSCLC with wild-type epidermal growth factor receptor (EGFR). A total of 70 patients were screened between March 2011 and December 2013, out of which 62 patients were enrolled in the study.
View Article and Find Full Text PDFMicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis.
Clin Res Hepatol Gastroenterol
September 2015
Maanshan Center for Clinical Laboratory, Maanshan Municipal Hospital Group, 45, Hubei Road, 243000 Maanshan, China.
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and it is the second leading cause of cancer-related deaths. Despite improvements in HCC therapy, the overall survival rate is still very low because of the late detection of the tumors. Thus, early detection of HCC offers the best chance of survival for patients.
View Article and Find Full Text PDFA systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: Focus on cutoff levels.
J Microbiol Immunol Infect
August 2015
Department of Microbiology, Chengdu Municipal Center for Disease Control and Prevention, Chengdu 610083, China.
Article Synopsis
- The study evaluated the diagnostic accuracy of the 1,3-β-D-glucan (BDG) assay for invasive fungal infections (IFI) by analyzing data from 28 studies, with 896 patients confirmed positive for IFI.
- The pooled results showed a sensitivity of 78%, specificity of 81%, and a significant diagnostic odds ratio, with a summary receiver operating characteristic (SROC) curve area of 0.8855, indicating strong test performance.
- For optimal diagnostic accuracy, the study recommends using a BDG cutoff value of 60 pg/mL, particularly aligning with the European Organization for Research and Treatment of Cancer/Mycoses Study Group's criteria.